SRR8518294
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.330
- MYC_TARGETS_V2+0.290
- KRAS_SIGNALING_DN+0.260
- E2F_TARGETS+0.250
- PANCREAS_BETA_CELLS+0.250
- SPERMATOGENESIS+0.250
- MYC_TARGETS_V1+0.240
- G2M_CHECKPOINT+0.230
- TNFA_SIGNALING_VIA_NFKB+0.190
- OXIDATIVE_PHOSPHORYLATION+0.100
Top 10 suppressed
- NOTCH_SIGNALING-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- ALLOGRAFT_REJECTION-0.350
- COMPLEMENT-0.340
- APICAL_JUNCTION-0.300
- UV_RESPONSE_DN-0.300
- IL2_STAT5_SIGNALING-0.290
- ANGIOGENESIS-0.280
- COAGULATION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-A6DE-01A-22R-A31N-07 | — | — | 0.803 |
| 2 | SRR1516061 | — | — | 0.767 |
| 3 | 20130300.LumB | — | B | 0.750 |
| 4 | SRR1516077 | — | — | 0.739 |
| 5 | TCGA-CX-7086-01A-11R-2081-07 | — | — | 0.736 |
| 6 | SRR8526725 | — | cohortSQ2 | 0.734 |
| 7 | SRR8518144 | — | E | 0.727 |
| 8 | MBCProject_3717_T3_RNA | — | B | 0.717 |
| 9 | SRR25043633 | — | — | 0.717 |
| 10 | ERR2208932 | — | — | 0.708 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.040 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.010 | Idelalisib | — uncovered |